December 29, 2011 — Navitoclax, a novel BH3 mimetic that blocks the function of BCL-2, has shown significant antileukemic activity in patients with chronic lymphocytic leukemia (CLL) in a phase 1 ...

Eli Lilly and Company (NYSE: LLY) today announced the details of presentations at the European Hematology Association (EHA) ...

Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with for years, and the real measure of a therapy is how it performs over the long ...

Progress against cancer doesn’t always arrive as headlines. Often, it shows up quietly in longer lives, better tolerability, ...

Ibrutinib normalizes RBC aggregation in CLL, potentially reducing thrombotic risks by mitigating blood flow complications. Obinutuzumab/venetoclax combination does ...

Several potentially practice-changing phase 3 trials alongside promising results in emerging strategies in chronic lymphocytic leukemia (CLL) presented at the 2025 American Society of Hematology ...

Double-exposed CLL patients have poor prognoses, with limited effective treatment options available, highlighting a significant unmet need. Potentially effective treatments include pirtobrutinib, ...

Researchers sought to compare the safety and effectiveness of zanubrutinib and ibrutinib in routine clinical practice.

Immunoglobulin replacement therapy in CLL patients does not reduce serious infection risk, despite increased usage over 14 years. The study found higher infection rates during immunoglobulin therapy ...